Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM, Mesa RA. Scherber RM, et al. Blood Rev. 2020 Jul;42:100716. doi: 10.1016/j.blre.2020.100716. Epub 2020 May 30. Blood Rev. 2020. PMID: 32593470 Free PMC article. Review.
The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatment refractory and progressive disease, prognosis has been characteristically poor. JAK inhibition with ruxolitinib or fedratinib thera …
The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatmen …
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R. Kuykendall AT, et al. Ann Hematol. 2022 Jan;101(1):139-146. doi: 10.1007/s00277-021-04683-w. Epub 2021 Oct 8. Ann Hematol. 2022. PMID: 34622316 Clinical Trial.
In conclusion, treatment with imetelstat was associated with longer overall survival compared to BAT (30 vs 12 months, respectively) in closely matched patients with MF after JAK inhibitor failure, warranting further evaluation of imetelstat in this poor-prognosis patient …
In conclusion, treatment with imetelstat was associated with longer overall survival compared to BAT (30 vs 12 months, respectively) in clos …
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C. Gerds A, et al. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e463-e468. doi: 10.1016/j.clml.2018.06.025. Epub 2018 Jun 28. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30115545
Following cessation of ruxolitinib, all patients received a first re-challenge course with improvement in symptoms and splenomegaly in 92% and 69%, respectively. Of the 4 patients who received a second re-challenge course of ruxolitinib, all had improvements in sple …
Following cessation of ruxolitinib, all patients received a first re-challenge course with improvement in symptoms and splenomegaly i …